Clinical Trials for Mesothelioma Patients: Cisplatin, Pemetrexed and Bevaiczumab

Read about a current clinical trial being conducted to study the effects of Cisplatin, Pemetrexed and Bevacizumab for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Purpose: To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab.

Requisite Conditions: Mesothelioma

Intervention: Drugs: Cisplatin, Pemetrexed and Bevacizumab

Study Phase, Type and Design: Phase II Interventional Study; Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Official Title: A Phase II Trial of Cisplatin, Pemetrexed and Bevacizumab in Untreated Malignant Mesothelioma

Primary Outcome Measures:
• progression free survival
Secondary Outcome Measures:
• response rate
• overall survival

Recruitment Information:
Recruitment Status: Recruiting
Enrollment: 65
Study Start Date: February 2006

Courtesy of ClinicalTrials.gov.

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney